Astria Therapeutics, Inc. (NASDAQ:ATXS – Get Free Report) has been assigned a consensus recommendation of “Buy” from the six research firms that are covering the company, Marketbeat Ratings reports. Five research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $25.20.
ATXS has been the topic of several recent analyst reports. HC Wainwright reiterated a “buy” rating and issued a $16.00 price target on shares of Astria Therapeutics in a research note on Tuesday. TD Cowen initiated coverage on Astria Therapeutics in a research report on Monday, July 29th. They issued a “buy” rating and a $35.00 target price on the stock. Wedbush reissued an “outperform” rating and set a $22.00 price target on shares of Astria Therapeutics in a research report on Tuesday. Evercore ISI upgraded shares of Astria Therapeutics to a “strong-buy” rating in a research note on Wednesday. Finally, Oppenheimer increased their price objective on shares of Astria Therapeutics from $25.00 to $26.00 and gave the company an “outperform” rating in a research note on Tuesday.
Get Our Latest Stock Analysis on ATXS
Institutional Investors Weigh In On Astria Therapeutics
Astria Therapeutics Stock Performance
Shares of NASDAQ:ATXS opened at $11.06 on Friday. The business’s 50-day simple moving average is $10.12 and its 200 day simple moving average is $11.37. The company has a market cap of $607.34 million, a P/E ratio of -4.77 and a beta of 0.73. Astria Therapeutics has a one year low of $4.26 and a one year high of $16.90.
Astria Therapeutics (NASDAQ:ATXS – Get Free Report) last posted its quarterly earnings data on Monday, August 12th. The biotechnology company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.05). Analysts predict that Astria Therapeutics will post -1.62 earnings per share for the current year.
About Astria Therapeutics
Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.
Read More
- Five stocks we like better than Astria Therapeutics
- Best Aerospace Stocks Investing
- Deere Rebounds on Earnings Beat, But Uphill Battle Remains
- Breakout Stocks: What They Are and How to Identify Them
- Mutual Funds vs Hedge Funds: What’s the Difference?
- Investing In Preferred Stock vs. Common Stock
- 3 Beaten-Down Tech Stocks That Shouldn’t Be Overlooked
Receive News & Ratings for Astria Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astria Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.